Hikma Pharmaceuticals PLC logo

Hikma Pharmaceuticals PLC

OTCPK:HKMPF (UK)   Ordinary Shares
$ 23.37 0 (0%) 11:08 PM EST
28.02
P/B:
2.40
Volume:
-
Avg Vol (2M):
808.00
Also Trade In:
Volume:
-
Avg Vol (2M):
808.00
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Hikma Pharmaceuticals PLC ( ) from 2009 to Mar 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hikma Pharmaceuticals PLC stock (HKMPF) PE ratio as of Mar 29 2024 is 28.02. More Details

Hikma Pharmaceuticals PLC (HKMPF) PE Ratio (TTM) Chart

To

Hikma Pharmaceuticals PLC (HKMPF) PE Ratio (TTM) Historical Data

Total 1195
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Hikma Pharmaceuticals PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-29 27.5 2024-01-25 27.7
2024-03-28 27.5 2024-01-24 28.9
2024-03-27 27.5 2024-01-23 28.9
2024-03-26 27.5 2024-01-22 28.9
2024-03-25 27.5 2024-01-19 28.9
2024-03-22 27.5 2024-01-18 29.1
2024-03-21 27.5 2024-01-17 29.1
2024-03-20 27.5 2024-01-16 29.0
2024-03-19 27.5 2024-01-12 29.0
2024-03-18 27.5 2024-01-11 27.6
2024-03-15 27.5 2024-01-10 27.6
2024-03-14 27.5 2024-01-09 27.6
2024-03-13 27.5 2024-01-08 27.6
2024-03-12 27.5 2024-01-05 27.6
2024-03-11 27.5 2024-01-04 27.6
2024-03-08 27.5 2024-01-03 26.8
2024-03-07 27.5 2024-01-02 26.8
2024-03-06 28.4 2023-12-29 26.8
2024-03-05 28.6 2023-12-28 26.2
2024-03-04 28.6 2023-12-27 34.0
2024-03-01 28.6 2023-12-26 34.0
2024-02-29 28.6 2023-12-22 32.8
2024-02-28 31.2 2023-12-21 32.8
2024-02-27 31.2 2023-12-20 32.8
2024-02-26 31.2 2023-12-19 32.8
2024-02-23 31.2 2023-12-18 32.8
2024-02-22 31.2 2023-12-15 33.0
2024-02-21 29.4 2023-12-14 33.0
2024-02-20 29.4 2023-12-13 33.0
2024-02-16 29.4 2023-12-12 33.0
2024-02-15 29.4 2023-12-11 33.0
2024-02-14 28.6 2023-12-08 33.4
2024-02-13 28.3 2023-12-07 33.4
2024-02-12 28.3 2023-12-06 33.4
2024-02-09 28.3 2023-12-05 33.4
2024-02-08 28.3 2023-12-04 33.4
2024-02-07 28.4 2023-12-01 33.0
2024-02-06 28.4 2023-11-30 33.0
2024-02-05 28.4 2023-11-29 33.0
2024-02-02 28.4 2023-11-28 33.0
2024-02-01 28.4 2023-11-27 32.9
2024-01-31 28.4 2023-11-22 31.9
2024-01-30 28.4 2023-11-21 31.9
2024-01-29 28.4 2023-11-20 31.9
2024-01-26 28.4 2023-11-17 31.9

Hikma Pharmaceuticals PLC (HKMPF) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.